SEARCH

SEARCH BY CITATION

Büyükçelik et al. raise a valid question regarding the relation between hyperglycemia and dose reduction during chemotherapy with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) for the treatment of acute lymphocytic leukemia. We reviewed the data and found that 62% of patients with hyperglycemia (defined as a random serum glucose level of ≥ 200 mg/dL on 2 or more determinations during the first 30 days of treatment) had a dose reduction at some time during treatment, compared with 60% of patients without hyperglycemia. Therefore, there does not appear to be an association between hyperglycemia and the risk for reduction in dose intensity in this patient population.

REFERENCES

  1. Top of page
  • 1
    Weiser MA, Cabanillas ME, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004; 100: 11791185.